Skip to content
Screener

Ligand Pharmaceuticals LGND Zerion — Gross carrying value

Other product segments

Qarziba
$101.3M

Similar metrics at other companies

Gentex logo
GNTXOther — Gross carrying value
$38.4M
Sirius XM logo
SIRISiriusXM — Gross Carrying Value
$8.61B0.0%
UDR logo
UDRNortheast Region — Real Estate Gross At Carrying Value
$4.03B+6.0%
UDR logo
UDRSoutheast Region — Real Estate Gross At Carrying Value
$1.79B+1.9%
UDR logo
UDRSouthwest Region — Real Estate Gross At Carrying Value
$1.96B+1.2%
UDR logo
UDRWest Region — Real Estate Gross At Carrying Value
$4.77B+1.0%

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
Line itemJune 30, 2026 / Gross carrying value(1)June 30, 2026 / AllowanceJune 30, 2026 / Net carrying value (1)December 31, 2025 / Gross carrying value(1)December 31, 2025 / AllowanceDecember 31, 2025 / Net carrying value(1)
Tolerance Therapeutics (Tzield®)25,470(99)25,37125,257(98)25,159
Ohtuvayre inventors19,957(179)19,77816,921(151)16,770
Elutia (CorMatrix)6,062(837)5,2256,607(1,107)5,500
AT2204,442(109)4,3335,132(132)5,000
Primrose mRNA3,281(98)3,1833,281(98)3,183
Zerion2,640(79)2,561
Others5,729(212)5,5175,769(214)5,555
Total financial royalty assets, net$209,699$(2,489)$207,210$222,375$(2,706)$219,669

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's zerion — gross carrying value?
Ligand Pharmaceuticals (LGND) reported zerion — gross carrying value of $2.64M in Q2 2026.
What does zerion — gross carrying value mean?
This represents the total historical cost or initial valuation of royalty-based intangible assets associated with the Zerion segment before any adjustments for impairment or allowances. It serves as a baseline measure of the capital deployed into the Zerion technology platform to acquire future revenue streams. Monitoring this value helps investors understand the scale of the company's investment in this specific drug discovery and development asset class.

Ask your AI about Ligand Pharmaceuticals's zerion — gross carrying value.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude